Testimony on Lomitapide to the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee
Public Citizen opposes the Food and Drug Administration’s approval of lomitapide because of the inadequacy of the clinical trial testing the drug and the lack of an effective risk management strategy for restricting use of the drug.